Get started
Author

Gil Fridberg

Observed name: G. Fridberg
ORCID: 0000-0003-3447-8793
Observed ORCID: 0000-0003-3447-8793
OpenAlex ID: A5079245308
Lesion location impact on functional recovery of the hemiparetic upper limb
2019 · Silvi Frenkel-Toledo, Gil Fridberg, et al. · PLoS ONE · 32
PDF
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion—A Phase 2, Prospective Interventional Study
2024 · Ron Ram, Odelia Amit, et al. · Transplantation and Cellular Therapy · 6
The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy
2023 · Gil Fridberg, Galit Horn, et al. · Cancers · 5
PDF
Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching
2023 · Gil Fridberg, Odelia Amit, et al. · Blood · 4
Smoldering Multiple Myeloma Progressing to Active Multiple Myeloma Vs De-Novo Active Multiple Myeloma - a Comparison of Disease Characteristics, Organ Involvement and Outcomes in a Real-Life Multicenter Retrospective Cohort Study
2023 · Yael C. Cohen, Gil Fridberg, et al. · Blood · 2
PDF
The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes—A Single-Center Longitudinal Cohort Analysis
2024 · Gil Fridberg, Odelia Amit, et al. · Cancers · 1
PDF
P966: Smoldering Multiple Myeloma (mm) Progressing to Active Mm During Follow-up: Reduced Bone Disease and Improved Progression-free and Overall Survival Compared to De-novo Newly Diagnosed Mm
2023 · Gil Fridberg, Tamir Shragai, et al. · HemaSphere · 1
UBE2E3 sustains PRC1.1 function and leukemic stemness in acute myeloid leukemia
2026 · Boaz Nachmias, Victoria Golan, et al. · Research Square
PDF
Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma
2026 · Gil Fridberg, Odelia Amit, et al. · Transplantation and Cellular Therapy
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
2026 · Iuliana Vaxman, Itai Zamir, et al. · Hematological Oncology
Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes
2026 · Gil Fridberg, Inbar Cohen, et al. · Cancers
PDF
Research Letter: Immune Cell Profiling in Lymphoma Patients Treated With CAR-T Cell Therapy and Nivolumab
2026 · Anwar Khatib, Amir Grau, et al. · Transplantation and Cellular Therapy
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study
2026 · Gil Fridberg, Odelia Amit, et al. · Haematologica
PDF
Sequential therapy with allogeneic HCT in patients aged ≥70 years with active AML: a singlecenter retrospective analysis
2026 · Odelia Amit, Gil Fridberg, et al. · Haematologica
PDF
Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study
2025 · Gil Fridberg, Odelia Amit, et al. · Blood
PDF
Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis
2025 · Odelia Amit, Gil Fridberg, et al. · Blood
PDF
Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells - a Pilot Study
2024 · Gil Fridberg, Odelia Amit, et al. · Blood
Targeted, Low Cost Epigenetic Microarray for AML and MDS Detection
2024 · Miriam Neaman, Mika Bell, et al. · Blood
Outcomes of Acute Myeloid Leukemia Patients Suffering from an Additional Active Malignancy Treated with Venetoclax and Azacitidine: A Single Center Experience
2023 · Yakir Moshe, Shai Levi, et al. · Blood
PDF
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis
2023 · Ron Ram, Ido Wolf, et al. · Blood
PDF
MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study
2023 · Inbar Cohen, Iuliana Vaxman, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
POSTER: MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study
2023 · Inbar Cohen, Iuliana Vaxman, et al. · Clinical Lymphoma Myeloma & Leukemia
P942: Multiple Myeloma Oligosecretory Relapse- a Cross Sectional Historical Cohort Study
2023 · Iuliana Vaxman, Itai Zamir, et al. · HemaSphere
Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes - a Single Center Longitudinal Cohort Analysis
2022 · Gil Fridberg, Odelia Amit, et al. · Blood
P1183: Car-t Morphological Characteristics and Dynamics in Peripheral Blood, Evaluated by a Novel Microscopy Platform
2022 · G. Fridberg, B.-Z. Katz, et al. · HemaSphere
Works count: 25
Citation count: 51
H-index: 4
I10-index: 1
Year
Topic
Type